Global Health Technologies Coalition (GHTC)

A diverse array of innovations is needed to prevent, diagnose, and treat the world’s most pressing #GlobalHealth challenges. Learn more ?? https://lnkd.in/e8iPrD2Z

Could disease-fighting antigens produced in a type of fungus accelerate how quickly protein-based vaccines are developed? CEPI is providing US$4.5 million to Italy's Fondazione Biotecnopolo di Siena for proof-of-concept research that will explore whether producing antigens in C1 filamentous fungus—applying technology owned by Dyadic International, Inc.—is a faster and cost-effective alternative to the more established route of producing antigens in mammalian cells.? The partnership supports the?100 Days Mission—a goal embraced by leaders of the G7 and G20 to reduce vaccine development timelines to a little over three months in response to a pandemic threat. Learn more ?? https://lnkd.in/ekAjnCyC

PATH welcomes the news that the first-ever maternal #RSV vaccine is now World Health Organization-prequalified to prevent RSV disease in infants. This milestone paves the way for broader access to prevention against the world’s leading cause of severe infant respiratory illness and hospitalization. Prequalification allows the vaccine to be procured by United Nations agencies and is a precursor to Gavi, the Vaccine Alliance support for vaccine use in low- and middle-income countries, where the RSV disease burden is greatest. “With a vaccine prequalified, now is an opportunity to focus on preparations for introduction and addressing remaining barriers to access and implementation,” says Dr. Clint Pecenka, director of PATH’s RSV vaccine program. Our full statement: https://bit.ly/4hLyZLr #VaccinesWork

The need to accelerate #innovation to strengthen global health security has never been greater. To this end, MMV and deepmirror have joined forces to harness #AI and machine learning in support of next-gen drug discovery. Together, we are developing Drug Design for Global Health, a new platform dedicated to accelerating research and facilitating access to cutting-edge tech for scientists in low- and middle-income countries. Chris Greenwood, Jeremy Burrows, Marina Garcia, Beno?t LALEU, Nikolaos Chalkias, Ph.D., Max Jakobs, Andrea Dimitracopoulos, Ryan Greenhalgh, Shannon Assaf, Viplov Jain, Janosch Menke, Cecilia Cabrera

?? Speaker Highlight: Bridging Science, Advocacy, and Practice to Combat AMR ?? Join us in person in Copenhagen or online for IDA’s hybrid event, "Bridging Science, Advocacy, and Practice: A Unified Approach to Combating Antimicrobial Resistance," on March 24 at 14:30 (CET). ?? We’re bringing together leading experts to explore collaborative, cross-sectoral solutions for tackling antimicrobial resistance (AMR) through a One Health approach. Meet Our Speakers: ?? Cóilín Nunan – Policy and Science Manager, Alliance to Save Our Antibiotics ?? Dominique L. Monnet – Head, AMR & Healthcare-Associated Infections, ECDC ?? Kim Lewis – Director, Antimicrobial Discovery Center, Northeastern University ?? Andrea Caputo Svensson, Ph.D. – Global Health Advisor, ReAct – ReAct - Action on Antibiotic Resistance ?? Dr. Chantal Morel – Health Economist, ESCMID - European Society of Clinical Microbiology and Infectious Diseases ?? Dr. Ute Wolff S?nksen – Head of DANMAP, Statens Serum Institut ?? Danilo Lo-Fo-Wong – Programme Manager, Control of AMR, WHO Regional Office for Europe ?? Kristian M?ller – Director, Veterinary & Quality Services, Danish Agriculture and Food Council ?? Venue: Jernesalen, Building 206, Statens Serum Institute, Copenhagen ?? Virtual access via Teams ?? Register now: https://lnkd.in/dhiaa64x #AntimicrobialResistance #OneHealth #GlobalHealth #AMR #PublicHealth #InfectiousDiseases #IDA #SciencePolicy

Are you from a Global South country interested in CEPI’s work and looking for ways to get involved? Check out CEPI’s Global South Fellowship Program, now accepting applications for its second cohort: https://lnkd.in/e3bZDHxp ? With four newly opened positions, the Program is an opportunity for individuals from Global South countries to further participate in global pandemic preparedness and response forums while acting as regional champions in support of the 100 Days Mission and CEPI’s vision for a pandemic-free future. The Fellowship Program aims to build capacity for future global health leaders, enhance readiness for the 100 Days Mission in the Global South, and facilitate knowledge exchange through improved global collaboration, in support of CEPI’s vision for a pandemic-free future. The Global South Fellow positions are situated in varied departments with specific focus areas within CEPI. ? ?? Epidemiology and Data Science: Support continuous improvement for Lassa clinical research in West Africa ?? Epidemiology and Data Science: Support Global South Leaders in Epidemic Analysis and Response Network (GS LEARN) ?? Laboratory Research and Innovations (LRI): Develop a sustainability plan for the LRI Laboratory Network ?? Strategy: Support a redesign of CEPI’s organisational Monitoring, Evaluation, and Learning approach Selected fellows will work from their home country, collaborating with CEPI on projects, engaging in local networks, and participating in training sessions. These new openings are an exciting opportunity to contribute to and work as part of an international and dynamic organisation, leading efforts to develop countermeasures that can be accessed quickly and equitably in the face of a future outbreak. ? ?? Fellowship duration: Up to 1 year, starting around June 2025. ? ?? Who can apply? Global health professionals, researchers, and advocates from the Global South with experience in pandemic preparedness and response. ? ?? Deadline: 17th April 2025. For more information about each Fellowship, including how to apply, please visit: https://lnkd.in/e3bZDHxp

NEW REPORT: check out Treatment Action Group (TAG)'s latest TB Vaccines Pipeline Report written by Mike Frick for the latest information on 17 vaccine candidates under clinical development. Decades of investment are starting to bear fruit, with multiple vaccine candidates in late-stage efficacy trials, including the recently launched IAVI-sponsored Phase TB IMAGINE trial in adolescents and adults in Kenya, South Africa, and Tanzania. As Frick reflects, progress is tenuous — there are too few novel candidates entering the pipeline, funding for TB vaccine research is growing too slowly, and political upheaval in the United States threatens to upend both scientific progress and public trust in vaccination with consequences for the world. Read the full report at https://lnkd.in/dB9Rijku

Heads up! Today is the last day for advance registration and reduced rates for #ASMicrobe 2025. Register here ?? https://asm.social/2kh

GHTC is now on Bluesky! Follow us for updates on #GlobalHealth R&D and to hear the latest on what our 50 members are up to! ??https://lnkd.in/eNBQJhye

[Press Release??] ? The GHIT Fund announced today announced today a total investment of approximately JPY 1.7 billion (USD 11.4 million) in five projects for the development of #schistosomiasis diagnostics and drugs for neglected tropical diseases (#NTDs). ? The GHIT Fund has decided to invest approx. JPY 780 million (USD 5.2 million1) in two projects to develop new diagnostics for schistosomiasis led by Drugs & Diagnostics for Tropical Diseases, a non-profit organization based in San Diego, USA, in collaboration with MBL (Medical & Biological Laboratories Co., Ltd.) , a Japanese manufacturer of clinical diagnostic kits and reagents,?Nagasaki University Institute of Tropical Medicine, the Kenya Medical Research Institute (KEMRI), and the Noguchi Memorial Institute for Medical Research (NMIMR). The project will advance the development of a rapid diagnostic test (RDT) for #Schistosoma mansoni, leveraging previous research findings and evaluating the diagnostic performance of the candidate RDT in endemic regions of Africa. In addition, the project team will develop a new serological RDT for Schistosoma haematobium. These tests are expected to be used as a low-cost, easy-to-use point-of-care (POC) diagnostics to support decision for Interruption of Transmission/Stopping Mass Drug Administration (MDA) and for subsequent Surveillance of the disease. ? In addition, the GHIT Fund will invest in the following three R&D projects for a total amount of approximately JPY 932 million (USD 6.2 million): 1) Phase I clinical trial project for dengue vaccine by VLP Therapeutics, Inc. and Nagasaki University 2) Screening project against chikungunya by Medicines for Malaria Venture (MMV) and Eisai Co., Ltd. 3) Screening project against #Chagas disease by Drugs for Neglected Diseases initiative (DNDi) and Shionogi & Co., Ltd.? ? Read the full article?? https://lnkd.in/gKZzuvp4 GHIT Fundは、#住血吸虫症 の診断薬や治療薬を中心とした顧みられない熱帯病（Neglected Tropical Diseases: NTDs）などの製品開発5件に、合計約17億円の投資を決定しました。 ? この度、米国サンディエゴに拠点を置きNTDsを中心とした診断薬を研究開発する非営利団体Drugs & Diagnostics for Tropical Diseasesが中心となり、臨床検査薬製造販売業者である（株）医学生物学研究所所、長崎大学?熱帯医学研究所、ケニア中央医学研究所、野口記念医学研究所などが取り組む住血吸虫症の診断薬の開発プロジェクト２つに合計約7.8億を投資します。本プロジェクトは、過去の研究成果を活かして、マンソン住血吸虫への適用を目指した迅速診断検査の開発とアフリカのまん延地域などで製品の性能評価を進めていきます。また、ビルハルツ住血吸虫を対象とした新たな血清学的迅速診断検査の開発も行います。この検査は、低コストで使いやすいポイント?オブ?ケア（POC）診断薬として、感染伝搬の遮断や集団薬剤投与（MDA）の終了判断、さらにはその後の疾患サーベイランスに活用されることが期待されています。 ? さらに、以下の3つの研究開発プロジェクトに合計約9.3億円の投資を決定しました。 (1)??VLP Therapeutics, Inc.および長崎大学によるデング熱ワクチンの第I相臨床試験のプロジェクト (2)??Medicines for Malaria Venture (MMV)とエーザイ株式会社によるチクングニアに対するスクリーニングプロジェクト (3)??Drugs for Neglected Diseases initiative (DNDi) と塩野義製薬株式会社によるシャーガス病に対するスクリーニングプロジェクト ? 詳細はこちら?? https://lnkd.in/gKXysCgm 国立大学法人 長崎大学 エーザイ株式会社